Evidence map›Paper›PMID 34697653›Full record

ArticleAnalytical and bioanalytical chemistry2021

Interlaboratory assessment of quantification of SARS-CoV-2 RNA by reverse transcription digital PCR.

Chunyan Niu, Xia Wang, Yongzhuo Zhang, Lin Lu, Di Wang, Yunhua Gao, Shangjun Wang, Jingyan Luo, Ying Jiang, Nuo Wang and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Analytical and bioanalytical chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Chunyan Niu *Center for Advanced Measurement Science, National Institute of Metrology, Beijing, China.
Xia Wang *Center for Advanced Measurement Science, National Institute of Metrology, Beijing, China.
Yongzhuo ZhangCenter for Advanced Measurement Science, National Institute of Metrology, Beijing, China.
Lin LuCenter for Reference Materials Research and Management (Office of National Research Center for Certified Reference Materials), National Institute of Metrology, Beijing, China.
Di WangCenter for Advanced Measurement Science, National Institute of Metrology, Beijing, China.
Yunhua GaoCenter for Advanced Measurement Science, National Institute of Metrology, Beijing, China.
Shangjun WangBiological Metrology Center, Nanjing Institute of Measurement and Testing Technology, Nanjing, China.
Jingyan LuoR & D Department, Guangdong Forevergen Medical Technology Co., Ltd, Foshan, China.
Ying JiangR & D Department, Mission Medical Technologies (Ningbo) Co., Ltd, Ningbo, China.
Nuo WangKey Laboratory of Emerging Pathogens and Biosafety, Centre for Biosafety Mega-Sciences, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
Yong GuoDepartment of Biomedical Engineering, School of Medicine, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Tsinghua University, Beijing, China.
Lingxiang ZhuTargetingOne Corporation, Beijing, China.
Lianhua DongCenter for Advanced Measurement Science, National Institute of Metrology, Beijing, China. donglh@nim.ac.cn.
National Institute of Metrology · CNChinese Academy of Sciences · CNShanghai Institute of Measurement and Testing Technology · CNTsinghua University · CN

Funding

National Key Research and Development Program of China 2017YFF0204605Special Technical Support Project of State Administration of Market Regulation 2020YJ039
6 · The paper itself

Abstract

The pandemic of the novel coronavirus disease 2019 (COVID-19) has caused severe harm to the health of people all around the world. Molecular detection of the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), played a crucial role in the control of the disease. Reverse transcription digital PCR (RT-dPCR) has been developed and used in the detection of SARS-CoV-2 RNA as an absolute quantification method. Here, an interlaboratory assessment of quantification of SARS-CoV-2 RNA was organized by the National Institute of Metrology, China (NIMC), using in vitro transcribed RNA samples, among ten laboratories on six different dPCR platforms. Copy number concentrations of three genes of SARS-CoV-2 were measured by all participants. Consistent results were obtained with dispersion within 2.2-fold and CV% below 23% among different dPCR platforms and laboratories, and Z' scores of all the reported results being satisfactory. Possible reasons for the dispersion included PCR assays, partition volume, and reverse transcription conditions. This study demonstrated the comparability and applicability of RT-dPCR method for quantification of SARS-CoV-2 RNA and showed the capability of the participating laboratories at SARS-CoV-2 test by RT-dPCR platform.

Indexed as

COVID-19HumansLaboratoriesLimit of DetectionReverse Transcriptase Polymerase Chain ReactionRNA, ViralSARS-CoV-2RNA, ViralCopy numberQuantificationRT-dPCRSARS-CoV-2

Identifiers

PMID34697653
PMCPMC8545465
OpenAlexW3208498318

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.